AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
glycyrrhizic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1325 | 1405-86-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A widely used anti-inflammatory agent isolated from the licorice root. It is metabolized to GLYCYRRHETINIC ACID, which inhibits 11-BETA-HYDROXYSTEROID DEHYDROGENASES and other enzymes involved in the metabolism of CORTICOSTEROIDS. Therefore, glycyrrhizic acid, which is the main and sweet component of licorice, has been investigated for its ability to cause hypermineralocorticoidism with sodium retention and potassium loss, edema, increased blood pressure, as well as depression of the renin-angiotensin-aldosterone system.
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.06 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.13 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 8.83 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.662 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 6.109 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.953 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.075 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 11.960 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 26.820 | % | High | 1 |
| herg | hERG pIC50 | 4.577 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.294 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.105 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 14.860 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PRKDC,SYK,TEK,TGFBR1 | 23 | |||
| kinase-selectivity-class | GRK2,MAP2K6 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.211 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 6.166 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 19.930 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.942 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 13.220 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 4.898 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 82.780 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 17.580 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 972.747 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 59.82 | 50.85 | 19 | 368 | 89276 | 110499636 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A05BA08 | ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY LIVER THERAPY, LIPOTROPICS Liver therapy |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:65232 | EC 3.4.21.5 (thrombin) inhibitor |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
Related Drugs by ATC class:
A05BA Liver therapy 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.84 | acidic |
| pKa2 | 3.48 | acidic |
| pKa3 | 4.89 | acidic |
| pKa4 | 10.8 | acidic |
| pKa5 | 11.96 | acidic |
| pKa6 | 12.18 | acidic |
| pKa7 | 12.79 | acidic |
| pKa8 | 13.33 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Corticosteroid 11-beta-dehydrogenase isozyme 2 | Enzyme | IC50 | 9.40 | CHEMBL | |||||
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Enzyme | IC50 | 8.22 | CHEMBL | |||||
| High mobility group protein B1 | Nuclear other | Kd | 4.06 | CHEMBL | |||||
| Beta-glucuronidase | Enzyme | IC50 | 4.01 | CHEMBL | |||||
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Enzyme | IC50 | 8.52 | CHEMBL | |||||
| Beta-glucuronidase | Enzyme | IC50 | 4.92 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000166344 | NUI |
| D00157 | KEGG_DRUG |
| 68797-35-3 | SECONDARY_CAS_RN |
| C0061751 | UMLSCUI |
| CHEBI:15939 | CHEBI |
| CHEMBL441687 | ChEMBL_ID |
| CHEMBL1927953 | ChEMBL_ID |
| CHEMBL1923952 | ChEMBL_ID |
| D019695 | MESH_DESCRIPTOR_UI |
| DB13751 | DRUGBANK_ID |
| 14982 | PUBCHEM_CID |
| 1367264 | RXNORM |
| 008271 | NDDF |
| 715362002 | SNOMEDCT_US |
| 4688 | IUPHAR_LIGAND_ID |
| 6FO62043WK | UNII |
| 6FO62043WK | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| BAMBOO SALT Eunganggo Jook Yeom Toothpaste | HUMAN OTC DRUG LABEL | 7 | 53208-459 | PASTE | 0.04 g | DENTAL | OTC monograph not final | 4 sections |
| BAMBOO SALT Eunganggo Jook Yeom | HUMAN OTC DRUG LABEL | 7 | 53208-505 | PASTE | 0.04 g | DENTAL | OTC monograph not final | 8 sections |
| YOUNGGAKSAN | HUMAN OTC DRUG LABEL | 4 | 72689-0021 | POWDER | 8.30 mg | ORAL | unapproved drug other | 7 sections |
| YOUNGGAKSAN | HUMAN OTC DRUG LABEL | 4 | 72689-0022 | POWDER | 8.30 mg | ORAL | unapproved drug other | 7 sections |
| YOUNGGAKSAN | HUMAN OTC DRUG LABEL | 4 | 72988-0019 | POWDER | 8.30 mg | ORAL | unapproved drug other | 7 sections |
| YOUNGGAKSAN | HUMAN OTC DRUG LABEL | 4 | 72988-0020 | POWDER | 8.30 mg | ORAL | unapproved drug other | 7 sections |
| THE SKIN HOUSE EGF COLLAGEN AMPOULE | HUMAN OTC DRUG LABEL | 1 | 73590-0019 | LIQUID | 0.10 g | TOPICAL | unapproved drug other | 7 sections |
| MELAO AFTER SHAVE COLOGNE | HUMAN OTC DRUG LABEL | 1 | 74458-454 | SPRAY | 0.50 g | TOPICAL | OTC Monograph Drug | 11 sections |
| BOP whiteningtoothpaste | HUMAN OTC DRUG LABEL | 2 | 82574-001 | GEL | 0.30 g | TOPICAL | unapproved drug other | 8 sections |
| Quick-Acting Wart Removal | HUMAN OTC DRUG LABEL | 4 | 83575-001 | LIQUID | 0.20 mg | CUTANEOUS | OTC monograph final | 12 sections |
| Hair GrowthShampoo | HUMAN OTC DRUG LABEL | 6 | 84148-026 | SHAMPOO | 0.10 g | CUTANEOUS | OTC Monograph Drug | 12 sections |